Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 20, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP14.67 per share, which was the price used for the re-investment of dividends paid on January 5, 2006.
Material Changes
The document reports an increase in shareholdings for specific individuals following the re-investment of dividends. There are no reported material changes to the company's financial position or operations in this filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It strictly details a compliance notification under Disclosure Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Notification of increased interests in Ordinary Shares by directors and connected persons via dividend re-investment.
- Share Price: GBP14.67 per share.
- Dividend Date: January 5, 2006.
- Individuals Notified: Mr R Bondy (179 shares), Mr M Dunoyer (66 shares), Dr D Pulman (102 shares), Mr A Witty (62 shares), and Mrs J Younger (158 shares).
- Financial Data: No revenue, earnings, or balance sheet data is included in this specific report.